Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients.

Hietala J, Syvälahti E, Vuorio K, Räkköläinen V, Bergman J, Haaparanta M, Solin O, Kuoppamäki M, Kirvelä O, Ruotsalainen U, et al.

Lancet. 1995 Oct 28;346(8983):1130-1.

PMID:
7475604
2.

Striatal presynaptic dopamine function in type 1 alcoholics measured with positron emission tomography.

Tiihonen J, Vilkman H, Räsänen P, Ryynänen OP, Hakko H, Bergman J, Hämäläinen T, Laakso A, Haaparanta-Solin M, Solin O, Kuoppamäki M, Syvälahti E, Hietala J.

Mol Psychiatry. 1998 Mar;3(2):156-61.

PMID:
9577840
3.

Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia.

Hietala J, Syvälahti E, Vilkman H, Vuorio K, Räkköläinen V, Bergman J, Haaparanta M, Solin O, Kuoppamäki M, Eronen E, Ruotsalainen U, Salokangas RK.

Schizophr Res. 1999 Jan 4;35(1):41-50.

PMID:
9988840
4.

Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.

Antonini A, Vontobel P, Psylla M, Günther I, Maguire PR, Missimer J, Leenders KL.

Arch Neurol. 1995 Dec;52(12):1183-90.

PMID:
7492293
5.

Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study.

McGowan S, Lawrence AD, Sales T, Quested D, Grasby P.

Arch Gen Psychiatry. 2004 Feb;61(2):134-42.

PMID:
14757589
6.

Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study.

Rinne JO, Portin R, Ruottinen H, Nurmi E, Bergman J, Haaparanta M, Solin O.

Arch Neurol. 2000 Apr;57(4):470-5.

PMID:
10768619
7.

6-[18F]fluoro-L-dopa uptake and [76Br]bromolisuride binding in the excitotoxically lesioned caudate-putamen of nonhuman primates studied using positron emission tomography.

Hantraye P, Loc'H C, Maziere B, Khalili-Varasteh M, Crouzel C, Fournier D, Yorke JC, Stulzaft O, Riche D, Isacson O, et al.

Exp Neurol. 1992 Feb;115(2):218-27.

PMID:
1531196
8.

D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.

Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordström AL, Hall H, Sedvall G.

Arch Gen Psychiatry. 1990 Mar;47(3):213-9.

PMID:
1968328
9.

Brain 6-[18F]fluorodopa metabolism in early and late onset of Parkinson's disease studied by positron emission tomography.

Nagasawa H, Tanji H, Itoyama Y, Saito H, Kimura I, Fujiwara T, Iwata R, Itoh M, Ido T.

J Neurol Sci. 1996 Dec;144(1-2):70-6.

PMID:
8994106
10.

The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.

Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden CD, Frackowiak RS.

Arch Neurol. 1990 Dec;47(12):1290-8.

PMID:
2123623
11.

Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia.

Huttunen J, Heinimaa M, Svirskis T, Nyman M, Kajander J, Forsback S, Solin O, Ilonen T, Korkeila J, Ristkari T, McGlashan T, Salokangas RK, Hietala J.

Biol Psychiatry. 2008 Jan 1;63(1):114-7. Epub 2007 Jul 26.

PMID:
17655830
12.

Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait.

Mateos JJ, Lomeña F, Parellada E, Mireia F, Fernandez-Egea E, Pavia J, Prats A, Pons F, Bernardo M.

Psychopharmacology (Berl). 2007 Apr;191(3):805-11. Epub 2006 Sep 22.

PMID:
17019564
13.

High levels of dopamine activity in the basal ganglia of cigarette smokers.

Salokangas RK, Vilkman H, Ilonen T, Taiminen T, Bergman J, Haaparanta M, Solin O, Alanen A, Syvälahti E, Hietala J.

Am J Psychiatry. 2000 Apr;157(4):632-4.

PMID:
10739427
14.

Striatal dopaminergic denervation in pallidopyramidal disease demonstrated by positron emission tomography.

Remy P, Hosseini H, Degos JD, Samson Y, Agid Y, Warter JM, Vidailhet M.

Ann Neurol. 1995 Dec;38(6):954-6.

PMID:
8526470
15.

Reduced striatal dopaminergic innervation shown by IPT and SPECT in patients under neuroleptic treatment: need for levodopa therapy?

Schwarz J, Scherer J, Trenkwalder C, Mozley PD, Tatsch K.

Psychiatry Res. 1998 Jul 15;83(1):23-8.

PMID:
9754702
16.

Increased striatal 18F-dopa uptake and normal glucose metabolism in idiopathic dystonia syndrome.

Otsuka M, Ichiya Y, Shima F, Kuwabara Y, Sasaki M, Fukumura T, Kato M, Masuda K, Goto I.

J Neurol Sci. 1992 Sep;111(2):195-9.

PMID:
1431986
17.

Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia.

Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF.

Nat Neurosci. 2002 Mar;5(3):267-71.

PMID:
11865311
18.

In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder.

Pearlson GD, Wong DF, Tune LE, Ross CA, Chase GA, Links JM, Dannals RF, Wilson AA, Ravert HT, Wagner HN Jr, et al.

Arch Gen Psychiatry. 1995 Jun;52(6):471-7.

PMID:
7771917
19.

6-[18F]fluorodopa metabolism in patients with hemiparkinsonism studied by positron emission tomography.

Nagasawa H, Saito H, Kogure K, Hatazawa J, Itoh M, Fujiwara T, Watanuki S, Seo S, Iwata R, Ido T.

J Neurol Sci. 1993 Apr;115(2):136-43.

PMID:
8482975
20.

6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography.

Elkashef AM, Doudet D, Bryant T, Cohen RM, Li SH, Wyatt RJ.

Psychiatry Res. 2000 Nov 20;100(1):1-11.

PMID:
11090720
Items per page

Supplemental Content

Write to the Help Desk